Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s
Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.
You may also be interested in...
Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping
Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.
Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.